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­e observation that amyloid radiotracers developed for Alzheimer’s disease bind to cerebral white matter paved the road to
nuclear imaging of myelin in multiple sclerosis. ­e lysolecithin (lysophosphatidylcholine (LPC)) rat model of demyelination
proved useful in evaluating and comparing candidate radiotracers to target myelin. Focal demyelination following stereotaxic LPC
injection is larger than lesions observed in experimental autoimmune encephalitis models and is followed by spontaneous
progressive remyelination. Moreover, the contralateral hemisphere may serve as an internal control in a given animal. However,
demyelination can be accompanied by concurrent focal necrosis and/or adjacent ventricle dilation. ­e inuence of these side
eects on imaging ndings has never been carefully assessed. ­e present study describes an optimization of the LPC model and
highlights the use of MRI for controlling the variability and pitfalls of the model. ­e prototypical amyloid radiotracer [11C]PIB
was used to show that in vivo PETdoes not provide sucient sensitivity to reliably track myelin changes and may be sensitive to
LPC side eects instead of demyelination as such. Ex vivo autoradiography with a uorine radiotracer should be preferred, to
adequately evaluate and compare radiotracers for the assessment of myelin content.
1. Introduction
Multiple sclerosis (MS) is a chronic inammatory de-
myelinating disorder aecting the quality of life, employ-
ment, and social relationships of approximately 2.1 million
people worldwide. ­e formation of focal demyelinated
lesions and progressive failure of remyelination is the main
characteristic of MS and further leads to axonal injury and
neuron loss [1]. Magnetic resonance imaging (MRI) is es-
sential for diagnosis and continuous management of MS [2].
However, conventional MRI measurements (lesion burden,
location, and type) correlate poorly with disability and lack
long-term prognostic value. New disease-modifying treat-
ments which promote remyelination are now entering
clinical evaluation [3]. ­erefore, an urgent challenge is to
identify the best objective, reliable, and predictive biomarker
of remyelination. ­ere is no consensus on which imaging
technique should be used. AdvancedMRI techniques such as
magnetization transfer imaging (MTI) [4] or myelin water
fraction (MWF) [5] are increasingly popular as research
tools but have not yet been standardized for widespread
clinical application. Quantication is not straightforward, as
myelin content is inferred indirectly from water binding to
lipid bilayer macromolecules [6, 7].
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By contrast, positron emission tomography (PET) may
provide more direct quantitative assessment of myelin con-
tent, by injection of a radiolabeled probe targeting myelin
proteins. Several independent groups have illustrated the
ability of [11C]PIB to detect white matter alterations in MS
[8, 9] and other pathological conditions [10, 11]. +ese
pioneering studies have stimulated the search for new myelin
radiotracers with enhanced speciﬁc (white matter) binding
ratio over nonspeciﬁc (gray matter) binding ratio [12] and,
ideally, with ﬂuorine-18 labeling to enable wider clinical use
[13, 14]. Among available models of demyelination, the
simple model consisting in intracerebral injection of lyso-
phosphatidylcholine (LPC, or lysolecithin) [15] appears at-
tractive for ﬁrst-step evaluation of radiotracers: the detergent
action of LPC produces focal demyelination, followed by
spontaneous progressive remyelination, while the contralat-
eral hemisphere may serve as an internal control in a given
animal. Hence, several imaging studies have used the LPC
model in rats, to evaluate MRI biomarkers [16, 17] or PET
radiotracers [12, 18]. However, as previously reported by
several groups, LPC-induced demyelination may be associ-
ated with concurrent focal necrosis [16, 18, 19] and/or
ventricle dilation [20]. +e inﬂuence of these side eﬀects
on imaging ﬁndings has never been carefully assessed.
+e present study describes an optimization of the LPC
model and highlights the use of MRI for controlling the
variability and pitfalls of the model. Using the prototypical
radiotracers [11C]PIB and [18F]AV-45, we show that (i) in
vivo PET does not provide suﬃcient sensitivity to reliably
track myelin changes in this model and (ii) ex vivo auto-
radiography should rather be used to adequately evaluate
and compare radiotracer performance.
2. Materials and Methods
2.1. Animals. A completed ARRIVE (Animal Research:
Reporting of In Vivo Experiments) guidelines checklist is
included as supplementary material (S1). All experiments
were carried out under a protocol approved by the local
ethical review board (“Comite´ d’e´thique pour l’Ex-
pe´rimentation Animale Neurosciences Lyon”, registration
code: C2EA-42), authorized by the FrenchMinistry of Higher
Education and Research (n°5892-2016063014207327v2), and
were in accordance with European directives on the pro-
tection and use of laboratory animals (Council Directive 2010/
63/UE, French decree 2013-118).
2.2. Housing. Adult male Sprague Dawley rats (ILAR code
Crl:CD(SD)) were ordered from Charles River (L’Arbresle,
France) and given a minimum of ﬁve days to acclimate to the
conventional housing facility, under temperature-controlled
(range 20–24°C) conditions and a 12 :12 h light-dark cycle,
with lights on at 07 : 00 and oﬀ at 19 : 00. Animals were housed
by group of six in open polycarbonate cages (Tecniplast,
2000P, L×W×H� 610× 435× 215mm, ﬂoor area 2065 cm2),
with stainless steel lids. Environmental enrichment included
spruce-based bedding of 2–4mm granulometry (Lignocel
3/4 s), round tinted polycarbonate tunnels (153× 75mm,
SERLAB), and hazel chew blocks (JR Farm). Animals were
given access to pellets of wheat and corn (Teklad Global 18%
Protein Rodent Diet, ENVIGO) and tap water ad libitum.
During housing, animals were monitored daily for health
status. At the start of the experiments, animals weighed
250–350 grams.
2.3. Surgery. Demyelination was induced by stereotaxic in-
jection of LPC (Sigma-Aldrich, ref. L4129) at 1% in saline
solution into the right corpus callosum and saline into the
contralateral site, infused at 0.1μl/min. +ree diﬀerent in-
jection conditions were successively tested (no randomization):
(i) In group 1 (n � 8), injection sites were adapted from
previous studies: AP −0.3mm; ML ±3.0mm; DV−3.5/−4.0/−4.5/−5.0mm; 2.5 μl each, from depth to
superﬁcial
(ii) In group 2 (n � 9), injection sites were slightly
adjusted: AP −0.3mm;ML ±3.3mm; DV −3.0/−3.7/−4.3/−5.0mm; 2.5 μl each, from depth to superﬁcial
(iii) In group 3 (n � 10), injection sites were restricted to
corpus callosum: AP −0.3mm; ML ±3.3mm; DV−2.8/−3.5mm; 2.5 μl each, from depth to superﬁcial
Rats were anesthetized with isoﬂurane inhalation in air in
an anesthesia induction box and then transferred to a ste-
reotaxic apparatus (Stoelting) equipped with amask delivering
isoﬂurane at 1.0–2.5% for the duration of the experiment.
Body temperature was maintained by a heating pad set at 37°C
and monitored using a rectal probe. Pain was controlled by
buprenorphine (Buprecare, Axience), a potent opioid anal-
gesic, injected subcutaneously at a dose of 0.05mg/kg 20min
before any surgical act was performed. A local analgesic
(lidocaine/prilocaine 5%, Pierre Fabre) was also applied on the
scalp before incision. After bilateral craniotomy, LPC and
saline were slowly infused with 30-gauge needles (RN type,
NH-BIO) via a tubing (Fine Bore Polythene Tubing, Portex,
SmithMedical Intl) connected to syringes installed in injection
pumps (World Precision Instruments). +e needles were left
in place for 2min and then slowly withdrawn. After injection,
the scalp was sutured, and an antiseptic (povidone-iodine) and
local analgesic (lidocaine) were applied. +e rats were then
allowed to recover from anesthesia. +e long-term action of
buprenorphine (ca 6 hours) allowed the animals to completely
recover without the need of a second administration. No
adverse events were observed.
Imaging studies were performed on an additional batch
of animals (10 animals injected as in group 3, with a single
animal being the experimental unit) and started 7 days
postinjection with MRI. One animal showed no MRI
changes and was excluded. In vivo PET, or ex vivo auto-
radiography, was performed between 8 and 15 days post-
injection in 9 animals, a period during which no signiﬁcant
spontaneous remyelination is expected [12, 17, 18].
2.4. In vivo Study. All imaging sessions were performed
under isoﬂurane anesthesia delivered in air by approved
systems (TEM Sega).
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2.4.1. MR Imaging. +e animals were placed in prone po-
sition in a dedicated plastic bed equipped with a stereotactic
holder (Bruker Biospec Animal Handling Systems) and
maintained under gaseous anesthesia delivered via a cone
mask throughout the MRI protocol. Body temperature was
maintained at 37± 1°C by thermoregulated water via a
circuit incorporated in the plastic bed. A respiratory sensor
was then placed on the abdomen to continuously monitor
respiration rate on a specialized device (ECG Trigger Unit
HR V2.0, Rapid Biomedical).
MRI acquisitions were performed on a horizontal 7T
Bruker Biospec MRI system (Bruker Biospin MRI GmbH)
with a set of 400mT/m gradients, controlled by a Bruker
ParaVision 5.1 workstation. A Bruker birdcage volume coil
(outer diameter� 112mm and inner diameter� 72mm) was
used for signal transmission and a Bruker single-loop surface
coil (25mm diameter), positioned on the head of the animal
to target the brain, for signal reception.
For the MRI protocol, 2D T2-weightedfat-saturated
images (T2WI) on the rapid acquisition with relaxation-
enhanced (RARE) method were obtained on axial slices.
Acquisition parameters were as follows: echo time (TE)
60ms, repetition time (TR) 5000ms, RARE factor� 8, and
average� 4. A total of 15.1mm slices were acquired with ﬁeld
of view (FOV) of 3 cm× 1.5 cm and matrix size of 256×128,
providing in-plane resolution of 117×117 microns, for
4minutes’ scan time.
2.4.2. [11C]PIB PET/CT Imaging. [11C]PIB was labeled as
previously described [21]. Radiochemical purity was >95%.
After catheterization of a caudal vein, animals (n � 4) were
positioned prone in a micro-PET/CT apparatus (Inveon,
Siemens) with the head centered in the ﬁeld of view (FOV).
Gaseous anesthesia was maintained via a cone mask, and
breathing rate was monitored throughout the experiment.
[11C]PIB with mean activity of 14.2MBq (383 μCi) (range,
9.6–20.2MBq) was injected intravenously as a bolus. Dy-
namic PET acquisition in list mode over 60min was started
immediately after radiotracer injection. CT scanning was
performed to correct attenuation and scatter. All PETimages
were reconstructed by 3D ordinary poisson ordered subsets
expectation-maximization (OP-OSEM3D) with 4 iterations
and a zoom factor of 2.+e reconstructed volume comprised
159 slices of 128×128 voxels, in a bounding box of
49.7× 49.7×126mm. Nominal in-plane resolution was
∼1.4mm full-width-at-half-maximum in the FOV center.
2.4.3. Image Analysis. Using the MIPAV (Medical Image
Processing, Analysis, and Visualization) application (https://
mipav.cit.nih.gov/), MR images were visually inspected in
search for areas in the corpus callosum exhibiting a nor-
malization of the natively hyposignal (Figure 1(a)) and for
any edematous hypersignal encompassing the corpus cal-
losum and adjacent areas (Figure 1(b)). A region of interest
(ROI) encompassing the abnormal area of the corpus cal-
losum was manually drawn on MR slices and mirrored onto
the contralateral corpus callosum. In addition, brain slices
were screened to identify and measure the maximal width of
the lateral ventricle along the mediolateral plane
(Figure 1(c)). Each of these two measurements was per-
formed by two operators (blind to other data). MR images
were then imported in the Inveon Research Workpackage
(IRW, Siemens) and registered onto PET/CT images.
Summed tracer uptake (% injected dose per gram) in the
ROIs was calculated from 20 to 40minutes’ acquisition.
2.5. Ex vivo Study
2.5.1. [18F]AV-45 Autoradiography. [18F]AV-45 was labeled
as previously described [22, 23]. Radiochemical purity was>95%. Under isoﬂurane anesthesia, animals (n � 5) were
intravenously injected with 12.6MBq (340 μCi) (range,
8.6–18.9MBq) [18F]AV-45 and euthanized 10min after
radiotracer injection. Brains were rapidly removed, snap-
frozen at −20°C, coronally cryosectioned into 30 μm slices,
and mounted on glass slides. After air-drying at room
temperature, slides were exposed to sensitive imaging plates
(BAS-IP MS 2025, Fujiﬁlm) for 4 hours. +e distribution of
radioactivity was then digitized on a bioimaging analyzer
(BAS-5000, Fujiﬁlm).
2.5.2. Myelin Histological Staining. Following autoradiog-
raphy, brain sections were postﬁxed with 4% formaldehyde
in PBS, then brieﬂy dehydrated in 70% ethanol. Slides were
incubated in 0.1% Sudan Black B (SBB) solution (Sigma-
Aldrich, ref. 199664) at room temperature for 10min,
washed in 70% ethanol for 10–30 s, then moved into distilled
water for mounting in aqueous medium (Roti-Mount, Carl
Roth). +e slides with demyelinated lesions were observed
and photographed under a microscope (Axioplan 2, Zeiss).
2.5.3. Image Analysis. Autoradiograms were visualized on
Multigauge software (Fujiﬁlm). ROIs were drawn manually
on the targeted injection sites in the corpus callosum by a
single operator, and lesion-to-contralateral uptake ratios
were calculated. Corresponding ROIs were also drawn
manually on histological images, and myelin content in
ipsilateral and contralateral corpus callosum were semi-
quantitatively measured by an experienced observer blind to
the autoradiography results, using Image-Pro Plus 6.0
software (Media Cybernetics) and expressed as optical
density per unit area. +e lesion-to-contralateral ratios were
then calculated for optical density per unit area. For each
animal, quantiﬁcation was performed on 4 brain sections
encompassing the whole volume showing a decreased
binding, hence resulting in 20 measurements.
2.6. Statistical Analysis. Data were analyzed on SPSS 19.0
software. Group comparisons were performed using
Kruskal–Wallis tests and Mann–Whitney test after binar-
ization of side-eﬀect detection. Slice-by-slice correlation
between autoradiography and histology measurements, as
well as correlation between operators, used Spearman’s tests.
+e signiﬁcance threshold was set at p< 0.05.
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3. Results
3.1. MRI-Based Optimization of LPC Injections.
Optimization of the injection protocol was driven by the
need to obtain a large area of demyelination in the corpus
callosum, so as to be clearly detected in vivo on PET.
However, necrosis and adjacent ventricular dilation are
pitfalls commonly reported after LPC injection
[12, 18–20]. In line with these reports, our ﬁrst attempts to
establish a pure model of demyelination highlighted the
need to keep a low LPC concentration (1%) and low in-
jection speed (0.1 μL/min) (data not shown). Because
visual postmortem examination of brain tissue, seen upon
cutting brains on a cryostat, may be biased by extraction
and processing, in vivo anatomical T2-weighted MRI was
used to evaluate diﬀerent injection protocols. Although
T2 contrast might be inﬂuenced by several concurrent
processes, pilot histological comparisons showed a fair
agreement between (i) the loss of the natively hypointense
contrast of corpus callosum and successful demyelination
(Figure 1(a)) and (ii) strong edematous hypersignals and
necrosis (Figure 1(b)). +erefore, in an eﬀort to provide
immediately available criteria for enrolling animals into a
subsequent PET protocol, the following simple MRI
metrics were used for evaluating the optimization process:
(i) manual delineation of signal abnormality on corpus
callosum as a surrogate for demyelination (Figure 1(a))
and (ii) manual measurement of the maximal width of the
lateral ventricle as a surrogate for abnormal dilation
(Figure 1(c)). Two operators independently performed
(a)
(b)
(c)
Figure 1: Comparison of MRI (T2WI, left column) and histology with Sudan black B (SBB, right column) at the injection sites. Postmortem
histological staining matched in vivo MRI observations. +erefore, anatomical MRI was used to (a) manually delineate areas of de-
myelination showing corpus callosum loss of hypointense contrast (in red, withmirror region of interest in green), (b) identify necrosis areas
with overt focal edematous hypersignal (arrow), and (c) measure the maximum width of the lateral ventricle along the mediolateral plane
(red segment) as an index of ventricular dilation after LPC injection.
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these two measurements with overall good reproducibility
(both correlations were signiﬁcant at the p< 0.01 level).
Importantly, deviations were below the resolution of PET
imaging. Raw data are provided as supplementary dataset
S2, and mean of the two measurements is reported
thereafter.
Figure 2 summarizes the results of this optimization
process in three experimental groups. In the ﬁrst group,
we adapted previously reported injection conditions
(group 1: 4 injection sites in striatum and corpus cal-
losum; total volume 10 μl). +is led to detectable edem-
atous hypersignals in half of the animals and a mean
ventricle width of 1.9 ± 0.5mm. In group 2, increasing the
distance between the 4 injection points and the lateral
distance from the bregma only slightly decreased the rate
of edema (4 over 9 animals) and reduced ventricle width
(1.7 ± 0.5 mm). As edematous foci were mainly observed
in the striatum, we simpliﬁed the injection protocol and
kept only two injection sites, at the lower and upper levels
of the corpus callosum (group 3; total volume 5 μl); with
this protocol, no animals showed focal edema, and ven-
tricle width was further reduced (1.2 ± 0.5mm). +e mean
volume of the abnormally normalized signal in the corpus
callosum increased in parallel with the reduction of LPC
side eﬀects, reaching 2.4 ± 0.9 mm3, which suggested in-
creased demyelination. However, these measurements
were not signiﬁcantly diﬀerent between groups (p> 0.05),
highlighting the residual variability of the model and
prompting us to examine how PET signals were aﬀected.
Would the following exclusion criteria have been applied:
(i) focal edematous hypersignal or (ii) maximal lateral
ventricle width >1.4mm (corresponding to the in-plane
PET resolution)—only 5 animals over 27 would have been
considered devoid of side eﬀects and selected (1 in group 1
and 4 in group 3). Of note, the volume of the abnormally
normalized signal in the corpus callosum, or “apparent”
demyelination, was signiﬁcantly higher in these 5 rats
than in the 22 others with at least one side eﬀect
(p � 0.03).
3.2. In vivo [11C]PIB PET. Among a new batch of animals,
injected in the conditions as group 3, four additional rats
were selected, to reﬂect the variety of lesions and pitfalls
following LPC injection. +ese animals underwent [11C]PIB
PET imaging between 8 and 15 days after stereotaxic in-
jection. Apparent demyelination volume on MRI and [11C]
PIB uptake within this volume and in a mirror volume in the
contralateral corpus callosum are reported in Table 1. In rats
A and B, [11C]PIB uptake was not decreased (ratio≥ 1)
despite a large demyelination area without edematous lesion
or ventricle dilation (Figures 3(a) and 3(b)). Rats C and D
presented a smaller demyelination area and one side eﬀect
each: focal edema in rat C (Figure 3(c)) and ventricle dilation
(max width> 1.4mm) in rat D (Figure 3(d)). MRI-driven
quantiﬁcation showed slightly decreased [11C]PIB uptake in
rat C (ratio 0.88) but not rat D (ratio 1.00). Importantly, PET
images highlighted decreased PIB uptake at the necrosis and
ventricle dilation sites. +ese results strongly suggested that
in vivo [11C]PIB PET imaging could not reliably detect
demyelination in the LPC-induced rodent model. Moreover,
side eﬀects of LPC injection may lead to false-positive de-
tection of demyelination when concurrent MRI is not
available. +ese qualitative but clear-cut results were con-
sidered as an endpoint for the PET study.
3.3. Ex vivo [18F]AV-45 Autoradiography. Because in vivo
detection of LPC-induced demyelination may be inaccurate
due to lack of spatial resolution and consequently decreased
sensitivity, 5 additional animals, injected in the same con-
ditions as group 3, underwent ex vivohigh-resolution au-
toradiography. Obtaining ex vivo images with a measurable
signal-to-noise ratio required changing from the carbon-11
PIB tracer to a ﬂuorine-18 radiotracer, such as [18F]AV-45.
At this 100 μm spatial resolution, pitfalls of the animal model
were easily identiﬁed as complete lack of signal in the 2D
images (Supplementary Figure S3) and could not be con-
founded with loss of binding in the demyelinated corpus
callosum. Binding in the ipsilateral corpus callosum was
clearly decreased in all animals (Figure 4(a)), conﬁrming the
MRI observations (Figure 4(b)). +e ipsi-to-contralateral
[18F]AV-45 uptake ratio, averaged from 4 brain sections
per animal, was similar in all ﬁve animals (0.78± 0.02).
Furthermore, subsequent myelin histology on the same
sections correlated visually (Figure 4(c)) and quantitatively
(Figure 4(d), r= 0.559, p � 0.005) with the corresponding
[18F]AV-45 signals.
4. Discussion
Unilateral LPC-induced demyelination has gained increased
popularity as a ﬁrst-line animal model for preclinical
evaluation of imaging biomarkers. Compared to other ro-
dent models of demyelination, it has the advantages of (i)
producing larger demyelination lesions than EAE models
[24] and (ii) not requiring another group of control animals,
as for transgenic shivered mice [25] or cuprizone-induced
demyelination [26]. +e goal of the present study was to set
up a workﬂow for the evaluation of new myelin radiotracers
using this LPC model in rats.
As a ﬁrst step, we observed, as previously reported, that
demyelination of the corpus callosum can be accompanied
by necrosis and/or ipsilateral ventricle dilation [19, 20].
Necrosis might be due to locally excessive LPC concen-
tration, and ventricle dilation is thought to be mediated by
inﬂammation. Here, we used anatomicalMRI tomonitor the
incidence of these side eﬀects in vivo (Figure 1). By targeting
white matter in the corpus callosum only (without striatum),
and by increasing the mediolateral distance of the injection
sites, we were able to reduce the proportion of animals
without any side eﬀects. Further reﬁnements of the injection
procedure might include the use of (i) glass-capillary
microneedles to minimize tissue damage and nonspeciﬁc
inﬂammatory responses [27] and (ii) T2 mapping instead of
T2-weighted imaging, so as to allow an operator-
independent,threshold-based, estimation of ventricle vol-
ume, and corpus callosum apparent demyelination [28].
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Although previous studies reported testing several in-
jection conditions [17, 19], the impact on imaging was never
assessed. +erefore, in the second step, a limited number of
PET imaging sessions with the reference radiotracer [11C]PIB
were conducted in additional animals representing the range
of pathological conditions observed after LPC injection. +e
results unambiguously showed that ipsilateral tracer uptake in
areas of demyelination was not decreased after LPC injection
(rats A and B), although their volume exceeded the resolution
of the small-animal PET scanner. Even more concerning was
the observation of apparently decreased uptake in the necrosis
site or enlarged ventricle (rats C and D). +erefore, in the
absence of individual MRI, PET-driven analysis might in-
correctly suggest demyelination (false-positive detection).
+ese results highlight the low sensitivity of [11C]PIB for
detecting demyelination in small-animal models. Several
factors may be put forward, including the mm-range reso-
lution of small-animal PET scanners, combined with the low
volume of highly myelinated axons in rodents, but also the
relatively high nonspeciﬁc binding of [11C]PIB. For ethical
reasons, we considered these qualitative but clear-cut results
as an endpoint for our PET study.
In the third step, we used ex vivo autoradiography
instead of in vivo imaging. Five additional animals were
injected with the ﬂuorine-18 radiotracer [18F]AV-45, be-
cause the short half-life of carbon-11 prevented accu-
mulating enough signal. It should be noted that in vitro
autoradiography is of little value for assessing radiotracer
binding to myelin, because white matter to gray matter
contrast entirely depends on washing conditions (data not
shown) and might not reﬂect in vivo uptake. Ex vivo
autoradiography appeared to be a viable strategy for
assessing radiotracer performance in the LPC model for
several reasons. First, side eﬀects were easily identiﬁed and
distinguished from the surrounding tissue on brain sec-
tions. Second, the signal drop in the injected corpus cal-
losum reached 20%, which was highly reproducible
(coeﬃcient of variation < 3% between the 5 rats) and
correlated with histology measurements. +ough quanti-
ﬁcation was restricted to discrete 2D measurements on
1
50%
(4/8)
Group Injection site Necrosis Maximum ventricle width (mm) Demyelination volume (mm3)
2
44%
(4/9)
3
0%
(0/10)
–3 –2 –1 0 1 2 3 4
3
Saline LPC
3
3.3
Saline LPC
3.3
3.3
Saline LPC
3.3
Figure 2: Optimization of the LPC injection protocol. LPC concentration (1% in saline) and infusion rate (0.1 μl/min) were kept constant
between the three groups. +e injection sites are shown in the corresponding Paxinos coronal diagram, with the following coordinates:
group 1, AP −0.3mm,ML ±3.0mm, DV −3.5/−4.0/−4.5/−5.0mm; group 2, AP −0.3mm,ML ±3.3mm, DV −3.0/−3.7/−4.3/−5.0mm; group
3, AP −0.3mm, ML ±3.3mm, DV −2.8/−3.5mm. Each site was infused with 2.5 μl of LPC, from depth to superﬁcial. +e rate of animals
exhibiting focal edematous hypersignals on MRI (as in Figure 1(b)) is given as a percentage (and number of animals out of total the group
number).+e graph shows the maximum ventricle width (measured along the mediolateral plane as in Figure 1(c), and arbitrarily expressed
as a negative value, in mm) and the total volume of corpus callosum exhibiting a normalization of the natively hypointense contrast
(measured as in Figure 1(a), in mm3).
Table 1: Quantiﬁcation of [11C]PIB uptake in ipsilateral (LPC) and contralateral (SAL) regions of interest (ROI) manually drawn onto T2WI
(as shown in Figure 1(a)). +e LPC-to-SAL ratio is expected to be< 1 in case of demyelination.
Rat MRI observations Vol. (mm3) of ROI on T2WI
[11C]PIB uptake (%ID/g)
LPC SAL Ratio
A Large demyelination 5.20 0.16 0.15 1.03
B Large demyelination 3.70 0.53 0.47 1.12
C Small demyelination with necrosis 2.20 0.25 0.29 0.88
D Small demyelination with ventricle dilation 1.90 0.23 0.23 1.00
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four brain sections per animal in this proof-of-concept
experiment, 3D-reconstruction methods dedicated to
autoradiography may be used in future studies to assess
signal drop in a continuous volume similar to in vivo
imaging [29]. Overall, these promising results are in line
with recent reports of repurposed ﬂuorine-18 labeled
amyloid radiotracers in MS patients (ﬂorbetapir or [18F]
AV-45 [30] and ﬂorbetaben or [18F]AV-1 [31]).
(a)
(b)
(c)
(d)
Figure 3: In vivo PETimaging with [11C]PIB. T2WIMRI is shown in the left column and overlaid with a 20min summed PETimage of [11C]
PIB in the right column. Rats A and B (a, b) exhibited a large demyelination area without necrosis or ventricle dilation. Rats C and D (c, d)
presented a smaller demyelination area and necrosis (c) or ventricle dilation (d).
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5. Conclusion
+is study aimed to draw attention to common pitfalls as-
sociated with LPC injections in the central nervous system
and their impact on nuclear imaging of myelin. While this
animal model is attractive for evaluating imaging biomarkers
of demyelination and remyelination, in vivo PET imaging in
small animalsmay be sensitive to side eﬀects of LPC injections
rather than real demyelination. We conclude that appropriate
use of this rodent model requires MRI to correctly identify
animals with pure demyelination and ex vivo autoradiography
to track spatial myelin changes with enough sensitivity. Al-
ternatively, longitudinal studies with in vivo PET imaging
could possibly be performed after LPC injection in larger
animals, such as rabbits [32], swine [33], or primates [34].
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